# NCT05028348 (NCT05028348)

> A Study of Combination of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Subject With Previously Treated Multiple Myeloma

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05028348
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: European Myeloma Network B.V.
- Conditions: Multiple Myeloma
- Interventions: Selinexor; Elotuzumab; Pomalidomide; Dexamethasone Oral
- Enrollment: 117
- Primary outcome: Progression-free survival (PFS)

## Indexed commentary on NCT05028348 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 3 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=nct05028348